Advaxis, SELLAS announce licensing agreement to develop antigen-targeting immunotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Advaxis Inc. granted SELLAS Life Sciences Group a license to develop a novel cancer immunotherapy agent using Advaxis’ proprietary Lm-based antigen delivery technology with SELLAS’ patented WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S).

Advaxis’ proprietary technology generates innate immune stimulation, alongside potent and sustained T-cell responses.

When combined with SELLAS’ WT1 antigens, this has the potential to precisely direct an immune response, yielding improved clinical activity against many cancer types that express WT1. SELLAS’ future clinical studies will investigate this capability in the presence of measurable residual or recurrent disease.

Galinpepimut-S has demonstrated positive phase II clinical results in acute myeloid leukemia and malignant pleural mesothelioma and positive early clinical data in multiple myeloma. It has been shown to induce strong immune responses (CD4+/CD8+) against the WT1 antigen and to access a broad range of HLA types.

Advaxis’s Lm-based antigen delivery technology has demonstrated the potential to induce an enhanced innate immune stimulation and generate specific T cells while reducing immune tolerance in the tumor microenvironment.

Advaxis will conduct all pre-clinical activities required for an IND filing.

Thereafter, SELLAS will be responsible for all clinical development and commercial activities. Advaxis will receive future payments of up to $358 million from SELLAS if development, regulatory, and commercial milestones are met.

Following any regulatory approval of the product candidate emanating from this particular program, SELLAS has agreed to pay Advaxis single-digit to low double-digit royalties based on worldwide net sales upon commercialization.

Table of Contents

YOU MAY BE INTERESTED IN

Arineta, a provider of cardiovascular imaging solutions, announced that its SpotLight Duo cardiac CT scanner has received 510(k) clearance from FDA for low-dose lung cancer screening. This clearance allows providers to use a single ultra-fast CT platform for both cardiac and lung imaging and diagnostics, delivering more complete care to high-risk patients.
Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.
In back-to-back congressional hearings earlier this week, HHS Secretary Robert F. Kennedy Jr. said that the massive staff and budget cuts over which he has presided during his nearly four months on the job as well as even bigger cuts still looming on the horizon are a part of a single plan.
Natalie Phelps, a 43-year-old mother of two, has stage 4 colorectal cancer. She has become a central figure in the controversy over the dysfunction the Trump administration’s RIFs and budget cuts have brought to NIH. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login